RESUMO
In pharmacokinetic (PK) analysis, conventional models are described by ordinary differential equations (ODE) that are generally solved in their Laplace transformed forms. The solution in the Laplace transformed forms is inverse Laplace transformed to derive an analytical solution. However, inverse Laplace transform is often mathematically difficult. Consequently, numerical inverse Laplace transform methods have been developed. In this study, we focus on extending the modeling functions of Nonlinear Mixed Effect Model (NONMEM), a standard software for PK and population pharmacokinetic (PPK) analyses, by adding the Fast Inversion of Laplace Transform (FILT) method, one of the representative numerical inverse Laplace transform methods. We implemented PREDFILT, a specialized PRED subroutine, which functions as an internal model unit in NONMEM to enable versatile FILT analysis with second-order precision. The calculation results of the compartment models and a dispersion model are in good agreement with the ordinary analytical solutions and theoretical values. Therefore, PREDFILT ensures enhanced flexibility in PK or PPK analyses under NONMEM environments.
Assuntos
Modelos Biológicos , Preparações Farmacêuticas/química , Farmacocinética , Software , Área Sob a Curva , Reprodutibilidade dos TestesRESUMO
The recent development of the first disease-modifying drug for Alzheimer's disease represents a major advancement in dementia treatment. Behind this breakthrough is a quarter century of research efforts to understand the disease not by a particular symptom at a given moment, but by long-term sequential changes in multiple biomarkers. Disease progression modeling with temporal realignment (DPM-TR) is an emerging computational approach proposed with this biomarker-based disease concept. By integrating short-term clinical observations of multiple disease biomarkers in a data-driven manner, DPM-TR provides a way to understand the progression of chronic diseases over decades and predict individual disease stages more accurately. DPM-TR has been developed primarily in the area of neurodegenerative diseases but has recently been extended to non-neurodegenerative diseases, including chronic obstructive pulmonary, autoimmune, and ophthalmologic diseases. This review focuses on opportunities for DPM-TR in clinical practice and drug development and discusses its current status and challenges.
Assuntos
Biomarcadores , Progressão da Doença , Humanos , Doença Crônica , Biomarcadores/metabolismo , Desenvolvimento de Medicamentos/métodos , Animais , Modelos BiológicosRESUMO
As Parkinson's disease (PD) progresses, there are multiple biomarker changes, and sex and genetic variants may influence the rate of progression. Data-driven, long-term disease progression model analysis may provide precise knowledge of the relationships between these risk factors and progression and would allow for the selection of appropriate diagnosis and treatment according to disease progression. To construct a long-term disease progression model of PD based on multiple biomarkers and evaluate the effects of sex and leucine-rich repeat kinase 2 (LRRK2) mutations, a technique derived from the nonlinear mixed-effects model (Statistical Restoration of Fragmented Time course [SReFT]) was applied to datasets of patients provided by the Parkinson's Progression Markers Initiative. Four biomarkers, including the Unified PD Rating Scale, were used, and a covariate analysis was performed to investigate the effects of sex and LRRK2-related mutations. A model of disease progression over ~30 years was successfully developed using patient data with a median of 6 years. Covariate analysis suggested that female sex and LRRK2 G2019S mutations were associated with 21.6% and 25.4% significantly slower progression, respectively. LRRK2 rs76904798 mutation also tended to delay disease progression by 10.4% but the difference was not significant. In conclusion, a long-term PD progression model was successfully constructed using SReFT from relatively short-term individual patient observations and depicted nonlinear changes in relevant biomarkers and their covariates, including sex and genetic variants.
Assuntos
Doença de Parkinson , Humanos , Feminino , Doença de Parkinson/genética , Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina/genética , Mutação , Biomarcadores , Progressão da DoençaRESUMO
The aim of this study was to elucidate the lifelong disease progression of chronic obstructive pulmonary disease (COPD) with biomarker changes and identify their influencing factors, by utilizing a new analysis method, Statistical Restoration of Fragmented Time-course (SReFT). Individual patient data (n = 1025) participating in the Study to Understand Mortality and MorbidITy (SUMMIT, NCT01313676), which was collected within the observational period of 4 years, were analyzed. The SReFT analysis suggested that scores of St. George's Respiratory Questionnaire and COPD assessment test, representative scores of the health-related quality of life (HRQOL) questionnaire, increased consistently for 30 years of disease progression, which was not detected by conventional analysis with a linear mixed effect model. It was estimated by the SReFT analysis that normalized forced expiratory volume in one second for age, sex, and body size (%FEV1) reduced for the initial 10 years from the onset of the disease but thereafter remained constant. The analysis of HRQOL scores and lung functions suggested that smoking cessation slowed COPD progression by approximately half and that exacerbation accelerated it considerably. In conclusion, this retrospective study utilizing SReFT elucidated the progression of COPD over 30 years and associated quantitative changes in the HRQOL scores and lung functions.